TP53 and B-cell chronic lymphocytic leukemia: We also used CAL-101, a drug targeting the p110δ subunit of PI3K, which demonstrated clinical efficacy against chronic lymphocytic leukemia and colon cancer cells regardless of p53 mutational status [53].